Related Experiment Videos
Propofol in chemotherapy-associated nausea and vomiting
1Department of Pharmacy, North Carolina Baptist Hospital, Winston-Salem, USA.
The Annals of Pharmacotherapy
|March 1, 1996
Summary
Propofol shows antiemetic properties, potentially aiding chemotherapy patients. Further research is needed to determine optimal dosing and its role in antiemetic therapy.
Area of Science:
- Anesthesiology
- Oncology
- Pharmacology
Background:
- Propofol is recognized for its anesthetic properties.
- Emerging evidence suggests propofol possesses antiemetic effects.
- Limited studies indicate potential benefits in chemotherapy-induced nausea and vomiting (CINV).
Purpose of the Study:
- To evaluate the antiemetic potential of propofol.
- To review existing literature on propofol's efficacy in managing CINV.
- To identify the need for further clinical trials.
Main Methods:
- Literature review of studies investigating propofol for antiemetic purposes.
- Analysis of reported efficacy and adverse effects.
- Assessment of current evidence regarding optimal dosing and patient selection.
Main Results:
- Propofol demonstrated antiemetic actions in limited reports.
- Benefits were observed as adjuvant therapy for highly emetogenic chemotherapy and monotherapy for moderately emetogenic chemotherapy.
- Adverse effects associated with propofol were minimal.
Conclusions:
- Propofol exhibits promising antiemetic properties.
- Optimal dosage and duration require investigation through Phase I studies.
- Well-designed clinical trials are essential to define propofol's role in antiemetic therapy, particularly for refractory cases.